CD Genomics-the genomics service company
Search
Search CD Genomics
CD Genomics
EXPLORE AREAS OF INTEREST
CD Genomics
Home / New blood test can accurately, quickly identify genetic mutations linked to NSCLC

New blood test can accurately, quickly identify genetic mutations linked to NSCLC

Bookmark and Share

New blood test can accurately, quickly identify genetic mutations linked to NSCLC

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive tissue biopsy, which may often be unnecessary and delays treatment. Recently, the research group from Biodesix, Inc develop a new method that can accurately and quickly identify genetic mutations associated with NSCLC, which could guide clinicians to treat patients in a personalized way.

The new method is based on the partitioning of DNA into droplets to detect specific circulating tumor DNA mutations and RNA variants in whole blood. It’s reported that among more than tested 1,600 samples, 10.5% had EGFR sensitizing, 18.8% EGFR resistance, 13.2% KRAS, and 2% EML4-ALK (anaplastic lymphoma kinase) mutations. The test showed high sensitivity (>80%) and specificity (100%) for detecting each type of mutation. In most cases, blood tests and tissue biopsies yielded the same results. Another advantage of the test is that it can be performed quickly: 94% of results were available within 72 hours of blood draw.

Hot Read
Feedback

Accept problems, make progress together, work hard to succeed

READ MORE
Featured Publications

Keep abreast of the latest application status

READ MORE
CONTACT CD GENOMICS

45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-275-3058
Fax: 1-631-614-7828
Email: info@cd-genomics.com